Skip to main content
. 2019 Apr 5;134(1):22–29. doi: 10.1182/blood.2019000215

Table 2.

Summary of toxicity

AE Grade 1 Grade 2 Grade 3 Grade 4
Total no. of AEs 308 (93) 96 (77) 21 (30) 7 (10)
Grade 2-4 TRAE
 Leukopenia 4 (7) 5 (13) 1 (3)
 Neutropenia 3 (7) 4 (10)
 Transaminitis 3 (10) 3 (7)
 Diarrhea/colitis 1 (3) 3 (7)
 Pneumonitis/dyspnea 3 (7) 1 (3)
 Hypothyroidism 4 (7)
 Rash 3 (7)
 Lymphopenia 1 (3) 1 (3)
 Thrombocytopenia 2 (7)
 Febrile neutropenia 1 (3)
 Pulmonary hemorrhage* 1 (3)
 Hyperthyroidism 1 (3)
 Arthritis 1 (3)
 Fatigue 1 (3)
 Neck pain 1 (3)
 Creatinine increase 1 (3)
 Blurred vision 1 (3)
Total no. of TRAEs 82 (67) 30 (47) 14 (27) 6 (10)
Grade 2-4 irAEs
 Transaminitis 2 (7) 3 (7)
 Pneumonitis/dyspnea/cough 4 (10) 1 (3)
 Diarrhea/colitis 1 (3) 2 (7)
 Rash 3 (7)
 Hypothyroidism 3 (3)
 Pulmonary hemorrhage* 1 (3)
 Hyperthyroidism 1 (3)
 Arthritis 1 (3)
 Creatinine increase 1 (3)
Total no. of irAEs 16 (33) 16 (33) 7 (20) 0 (0)

“Treatment-related” refers to AEs judged to be at least possibly related to study treatment. The number of patients, expressed as the percentage of total patients, is given in parenthesis for grade 2-4 TRAEs. Events are ordered by frequency.

*

In a patient with prior cavitary tumor lesion.